Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous versus intramuscular meglumine antimoniate for cutaneous leishmaniasis
IRCT20210823052264N4Phase 3Completed
- Sponsor
- Combined Military Hospital Quetta
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Combined Military Hospital Quetta. Primary endpoint: Clinical Response. Started Apr 2024; status: completed.
02
Drugs
meglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20210823052264N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210823052264N4.